Signatera, Prospera And Renasight Will Transform Diagnostics
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 20 Analysts
Published
11 May 25
Updated
24 Jul 25
AnalystConsensusTarget's Fair Value
US$192.78
30.2% undervalued intrinsic discount24 Jul
US$134.58
1Y
37.5%7D
-2.5%